COVID-19 treatment is still being developed by different medical experts and researchers across the globe. A new study showed that remdesivir and plasma might be the best treatment for the global coronavirus pandemic. However, other drugs are needed to make an ultimate cure.
According to NBC News' latest report, the remdesivir has a capability to treat coronavirus--many different studies claimed this, which will soon enter a new stage of research, even though the study's current phase analysis is not yet completed.
The report stated that the new phase is a sign that experiments conducted to find the efficient combination of drugs to cure COVID-19 have accelerated, as infected cases rise in many U.S. states.
"It's very intense work, a nonstop process," said the principal investigator for the ongoing remdesivir trial, Dr. Andre Kalil. The National Institute of Allergy and Infectious Diseases sponsored the drug trial.
Dr. Kalil's research team conducted a study in May, which showed that remdesivir reduces patients' time in the hospital by about four days, from 15, on average, to 11. The report stated that remdesivir alone will not be enough to treat the virus and need a cocktail of medicines since the study's results showed that it did not appear to lower deaths from the novel coronavirus.
Remdesivir and plasma may be a cure for COVID-19, but...
The maker of remdesivir, Gilead Sciences, confirmed that the drug will be tested in combination with another drug called tocilizumab, another rheumatoid arthritis drug sold as Actemra. The immune system's hyperinflammatory response to infection will be targeted by the new phase of the study, which will eventually include three or four medications, as confirmed by Kalil.
According to NBC News, convalescent plasma is another key treatment for COVID-19. The acting director of the Biomedical Advanced Research and Development Authority (BARDA), Gary Disbrow, informed a Senate Appropriates subcommittee during a hearing on Thursday, July 2, that the demand for the antibody-rich blood product from patients who recovered from COVID-19 has been high, with an estimated 25,000 patients already transfused in the United States.
On the other hand, a new drug candidate called Epo is on its way. According to Medical Express's latest report, the researchers at the Max-Planck Institute of Experimental Medicine in Gottingen claimed that the doping agent Epo, a medication for anemia also known as Erythropoietin, can also be efficient at eliminating the novel coronavirus.
Patients can be protected from long-term neurological effects when the SARS-CoV-2 virus attacks the brains. The study shows the positive effects of anemia medicine in initial case studies.
According to the report, a randomized clinical trial is currently planned by the researchers to investigate the effects of Epo treatment in coronavirus patients systematically. BMC Part of Springer Nature published the results of the study on June 16.